Esperion Therapeutics (NASDAQ:ESPR) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research note issued to investors on Tuesday morning, Benzinga reports. Needham & Company LLC currently has a $8.00 price objective on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a buy rating and issued a $16.00 price target on shares of Esperion Therapeutics in a report on Monday, March 25th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Esperion Therapeutics currently has a consensus rating of Hold and a consensus price target of $9.33.

Esperion Therapeutics Price Performance

NASDAQ:ESPR opened at $2.37 on Tuesday. The business has a fifty day simple moving average of $2.32 and a two-hundred day simple moving average of $2.07. Esperion Therapeutics has a 1 year low of $0.70 and a 1 year high of $3.40. The company has a market capitalization of $448.88 million, a P/E ratio of -1.12 and a beta of 0.89.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03. The firm had revenue of $32.25 million during the quarter, compared to analysts’ expectations of $26.84 million. During the same period in the prior year, the business earned ($0.76) earnings per share. As a group, analysts anticipate that Esperion Therapeutics will post -0.68 earnings per share for the current year.

Institutional Investors Weigh In On Esperion Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Wasatch Advisors LP boosted its stake in Esperion Therapeutics by 2.7% during the first quarter. Wasatch Advisors LP now owns 9,129,647 shares of the biopharmaceutical company’s stock valued at $24,467,000 after buying an additional 238,544 shares during the period. Armistice Capital LLC bought a new stake in Esperion Therapeutics during the fourth quarter valued at $9,568,000. Monaco Asset Management SAM boosted its stake in Esperion Therapeutics by 68.5% during the third quarter. Monaco Asset Management SAM now owns 1,171,779 shares of the biopharmaceutical company’s stock valued at $1,148,000 after buying an additional 476,477 shares during the period. GSA Capital Partners LLP boosted its stake in Esperion Therapeutics by 1.0% during the fourth quarter. GSA Capital Partners LLP now owns 1,128,149 shares of the biopharmaceutical company’s stock valued at $3,373,000 after buying an additional 11,494 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in Esperion Therapeutics by 120.1% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 413,704 shares of the biopharmaceutical company’s stock valued at $405,000 after buying an additional 225,767 shares during the period. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.